Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Mar 2028 → Aug 1, 2028
See other at-risk trials from Mayo Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 1, 2026 to Aug 1, 2027
    • Primary and study completion pushed from Mar 2028 to Aug 1, 2028
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Start date: May 2026 to Aug 1, 2026v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Mayo Clinic
1,025 trials monitored
See 131 trials at risk
The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.
Trial Details
NCT Number NCT07556484
Lead Sponsor Mayo Clinic
Conditions
(from sponsor)		 Diffuse Alveolar Hemorrhage, Antineutrophil Cytoplasmic Antibody Positive Vasculitis
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov